medigraphic.com
ISSN 1561-2988 (Print)

2013, Number 3

<< Back Next >>

Rev Cubana Farm 2013; 47 (3)

Microneedles and Transcutol® as transdermal penetration enhancers of sibutramine formulated in a transdermal patch

Serrano CP, Escobar CJJ, Morales HEA, Domínguez DCL, Abrego RVH

Language: Spanish
References: 17
Page: 289-299
PDF size: 430.96 Kb.


ABSTRACT

Introduction: the main permeation barrier is the skin. Although it is almost an impermeable barrier to most substances, new ways have been examined to improve its permeability by using new technologies such as microneedles and chemical enhancers like Transcutol®.
Objective: to develop and to characterize a transdermal patch containing sibutramine hydrochloride as model drug and using microneedles and Transcutol® as transdermal drug delivery enhancers.
Methods: Physicochemical characterization of sibutramine hydrochloride patches using polarized light microscopy, bioadhesion, tensile strength studies. The diffusion studies were performed in Franz-type diffusion cells with human abdominal skin as a sort of membrane between both compartments. The active ingredient was quantified through capillary electrophoresis.
Results: bioadhesive patches were obtained, with adequate stability of sibutramine hydrochloride in the polymer matrix of chitosan. The use of microneedles and Transcutol® increased sibutramine hydrochloride delivery through the human skin when compared with the control patch. The flow rates were 0.0649 mg.cm-2.h-1 and 0,0816 mg.cm-2.h-1 in the enhanced patch by using 1 and 2 mm microneedles respectively, in comparison with flow rates of 0,0527 mg.cm-2.h-1 and 0.0554 mg.cm-2.h-1 for the control patch having no enhancing agent with 1 and 2 mm microneedles respectively.
Conclusions: the results show that it is possible to use Transcutol® and microneedles to increase the delivery of potent drugs having a structure similar to that of sibutramine through transdermal administration. All this generates new alternatives to oral pharmaceuticals in order to treat ailments and diseases.


REFERENCES

  1. Soler Ranzani L. Desarrollo y evaluación biofarmacéutica de un sistema de administración transdérmica de alprazolam [tesis doctoral]. Barcelona: Universidad de Barcelona, Facultad de Farmacia; 2006.

  2. Escobar Chávez JJ. Estudio de la penetración a través de la piel de naproxeno sódico utilizando agentes promotores de penetración (azona y trancutol), y de dicluconato de clorhexidina mediante iontoforesis [tesis doctoral]. Estado de México: FESC UNAM; 2006.

  3. Ávila Avalos M. Métodos convencionales actualmente empleados para estudios de penetración percutánea [tesis]. Estado de México: FESC UNAM; 2010.

  4. Serrano Castañeda P. Uso de microagujas para hacer más eficiente el paso de clorhidrato de sibutramina a través de piel humana formulado en parches transdérmicos de una matriz polimérica de quitosán con Transcutol [tesis]. Estado de México: FESC UNAM; 2011.

  5. Escobar Chávez JJ, Bonilla Martínez D, Villegas González MA, Molina Trinidad E, Casas Alancaster N, Revilla Vázquez AL. Microneedles: A valuable physical enhancer to increase transdermal drug delivery. J Clin Pharmacol. 2011;51(7):964-77.

  6. Escobar Chávez JJ, Rodríguez Cruz IM, Domínguez Delgado CL. Chemical and Physical enhancers for transdermal drug delivery. In: Gallelli L, editor. Pharmacology. Rijeka: InTech; 2012. p. 397-433.

  7. Escobar-Chávez JJ, Merino V, editors. Current Technologies to increase the Transdermal Delivery of Drugs. The Netherlands: Bentham Science Publishers; 2010.

  8. Domínguez-Delgado CL, Rodríguez-Cruz IM, López-Cervantes M. The skin a valuable route for administration of drugs. In: Escobar-Chávez JJ, Merino V, editors. Current Technologies To Increase The Transdermal Delivery Of Drugs. The Netherlands: Bentham Science Publishers Ltd; 2010. p. 1-22.

  9. Escobar-Chávez JJ, Merino V, Díez Sales O, Nácher Alonso A, Ganem Quintanar A, Herráez M, Merino Sanjuán M. Transdermal nortriptyline hydrochloride patch formulated within a chitosan matrix intended to be used for smoking cessation. Pharm Develop Technol. 2011;16(2):162-9.

  10. Escobar-Chavez JJ, Quintanar-Guerrero D, Ganem-Quintanar A. In vivo skin permeation of sodium naproxen formulated in PF-127 gels: Effect of AzoneR and Transcutol®. Drug Develop Industr Pharm. 2005;31(4-5):447-54.

  11. Ammar HO, Salama HA, El-Nahhas SA, Elmotasem H. Design and evaluation of chitosan films for transdermal delivery of glimepiride. Curr Drug Delivery. 2008;5(4):290-8.

  12. Albasarah YY, Somavarapu S, Stapleton P, Taylor KM. Chitosan-coated antifungal formulations for nebulisation. J Pharm Pharmacol. 2010;62(7):821-8.

  13. Harris R, Lecumberri E, Heras A. Chitosan-genipin microspheres for the controlled release of drugs: clarithromycin, tramadol and heparin. Marine Drugs. 2010;8(6):1750-62.

  14. Jintapattanakit A, Peungvicha P, Sailasuta A, Kissel T, Junyaprasert VB. Nasal absorption and local tissue reaction of insulin nanocomplexes of trimethyl chitosan derivatives in rats. J Pharm Pharmacol. 2010;62(5):583-91.

  15. Escobar Chávez JJ, Merino Sanjuán V, López Cervantes M, Urban Morlan Z, Piñon Segundo E, Quintanar Guerrero D, Ganem Quintanar FA. Tape-Stripping Technique as a Method for Drug Quantification in Skin. J Pharm Pharmaceut Sci. 2008;11(1):104-30.

  16. Hsieh Dean S. Drug permeation enhancement theory and applications. Indiana: Marcel Dekker Inc.; 1994. p. 3-24, 95-104.

  17. Wokovich MA, Prodduturi S, Doub HW, Hussain SA. Transdermal drug delivery system (TDDS) adhesion as a critical safety, efficacy and quality attribute. Eur J Pharm Biopharm. 2006;64:1-8.




2020     |     www.medigraphic.com